2QK Stock Chart & Stats
€42.24
-€2.40(-5.83%)
At close: 4:00 PM EST
€42.24
-€2.40(-5.83%)
Day’s Range― - ―
52-Week Range€23.00 - €49.12
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€5.87B
Enterprise Value€5.40B
Total Cash (Recent Filing)€479.94M
Total Debt (Recent Filing)€205.67M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Aug 12, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.45
Shares Outstanding119,828,340
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)20.58
Price to Sales (P/S)0.00
P/FCF Ratio-16.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€52.18Price Target Upside23.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.79
Revenue Forecast (FY)€5.69M
Bulls Say, Bears Say
Bulls Say
BLA Acceptance & PDUFA DateRegulatory acceptance with a firm PDUFA date materially reduces binary uncertainty and creates a clear pathway to commercial approval. Over the next several months this can transition Scholar Rock from a pure R&D firm toward a revenue-generating commercial-stage biotech, unlocking launch planning, payer engagement, and milestone/value realization.
Dual Fill-Finish Manufacturing PathHaving an alternative, already-filed fill-finish supplier materially strengthens supply-chain resilience and lowers single-source manufacturing risk. This durable operational redundancy supports launch continuity if one site faces regulatory constraints and improves the company's ability to meet demand and execute commercialization plans.
Cash Position & Financing OptionalityA sizable cash balance plus multiple contingent financing levers (debt facility option, ATM proceeds, priority review voucher monetization) provides a multi-month runway and strategic optionality. This reduces immediate dilution risk and supports commercial launch investments and late-stage trials while approval-related milestones are resolved.
Bears Say
No Product Revenue; Widening LossesThe company remains pre-revenue with rapidly widening net losses, meaning long-term viability hinges on successful commercialization or sustained external funding. Persistent negative earnings will erode equity and force reliance on capital markets, creating dilution risk and constraining strategic flexibility absent product sales.
Large Cash Burn & Weak Cash GenerationSustained, large operating cash outflows indicate the business is heavily cash consumptive. Over a multi-month horizon this amplifies dependency on financing and heightens refinancing/dilution risk, limiting the company's ability to self-fund launches or additional R&D if capital markets tighten or milestone payments fall short.
Manufacturing-Related Approvability RiskRegulatory classification of a key fill-finish site is an enduring binary risk to approval and timing. An adverse outcome could delay or limit U.S. approval and complicate EU timelines tied to FDA decisions, forcing increased reliance on backup suppliers or remedial actions that raise costs and slow commercial roll-out.
Scholar Rock Holding News
2QK FAQ
What was Scholar Rock Holding’s price range in the past 12 months?
Scholar Rock Holding lowest stock price was €23.00 and its highest was €49.12 in the past 12 months.
What is Scholar Rock Holding’s market cap?
Scholar Rock Holding’s market cap is €5.87B.
When is Scholar Rock Holding’s upcoming earnings report date?
Scholar Rock Holding’s upcoming earnings report date is Aug 12, 2026 which is in 33 days.
How were Scholar Rock Holding’s earnings last quarter?
Scholar Rock Holding released its earnings results on May 07, 2026. The company reported -€0.725 earnings per share for the quarter, missing the consensus estimate of -€0.699 by -€0.026.
Is Scholar Rock Holding overvalued?
According to Wall Street analysts Scholar Rock Holding’s price is currently Undervalued.
Does Scholar Rock Holding pay dividends?
Scholar Rock Holding does not currently pay dividends.
What is Scholar Rock Holding’s EPS estimate?
Scholar Rock Holding’s EPS estimate is -0.73.
How many shares outstanding does Scholar Rock Holding have?
Scholar Rock Holding has 119,828,340 shares outstanding.
What happened to Scholar Rock Holding’s price movement after its last earnings report?
Scholar Rock Holding reported an EPS of -€0.725 in its last earnings report, missing expectations of -€0.699. Following the earnings report the stock price went down -1.313%.
Which hedge fund is a major shareholder of Scholar Rock Holding?
Currently, no hedge funds are holding shares in DE:2QK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Scholar Rock Holding Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€52.18 (23.53% Upside)
€52.18 (23.53% Upside)
Blogger Sentiment
Bullish
DE:2QK Sentiment 70%
Sector Average 69%
Sector Average 69%
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.63%
12-Months-Change
Fundamentals
Return on Equity
-163.52%
Trailing 12-Months
Asset Growth
31.33%
Trailing 12-Months
Company Description
Scholar Rock Holding
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
2QK Company Deck
2QK Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum: FDA accepted the BLA with a clear PDUFA date (Sept 30, 2026), the company has created dual manufacturing paths (second facility supplying product in early Q3), European review appears on track for midyear, and the balance sheet and commercial infrastructure were strengthened during the quarter. Key risks remain focused on regulatory classification of the Catalent Indiana site, continued manufacturing/regulatory uncertainty until that classification, high pre-commercial operating spend, and the need to monetize financing levers (debt/ATM/PRV). On balance, the material positive developments (BLA acceptance, dual fill-finish strategy, clear supply path, strong cash position, pipeline progression and commercial readiness) outweigh the remaining lowlights and uncertainties.View all DE:2QK earnings summaries2QK Stock 12 Month Forecast
Average Price Target
€52.18
▲(23.53% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Xenon
―
Immunovant
―
NewAmsterdam Pharma Company
―
Options Prices
Currently, No data available
---